Who
Jasper Bos
Director
Company insider
Files Form 4 as: Director, Braveheart Bio; Director, enGene Therapeutics.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 15 Jun 2024
- Last trade
- 5 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | BRVE Braveheart Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 Jun 2024filed 18 Jun 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.